Boehringer Ingelheim acquires Global Stem Cell Technology
Jan Spaas, CEO of GST.
Boehringer Ingelheim has acquired Global Stem Cell Technology (GST), a Belgian biotech firm that develops stem cell products for dogs and horses.
The acquisition follows Boehringer Ingelheim's partnership with GST in 2018. In 2019, the companies launched Arti-Cell® Forte in Europe, the first-ever stem cell product in the veterinary sphere granted marketing authorisation by the European Commission.
In a press release, Boehringer Ingelheim states that the acquisition and integration of GST will accelerate the development pipeline of Boehringer Ingelheim while maintaining its focus on setting new standards of care for animals.
Jean-Luc Michel, Head of Global Strategic Marketing, Boehringer Ingelheim Animal Health, commented: "Collaboration with external partners plays an essential role in helping us expand our portfolio. After two years of a very successful partnership, we have decided to acquire GST. We are convinced that its expertise in the field of state-of-the-art stem cell products will help us bring even more innovative solutions to our customers."
Jan Spaas, CEO of GST added: “Boehringer Ingelheim wants to lead a new wave of innovation in the veterinary field. This ambition is a natural fit with GST’s management, staff and vision. From the very beginning, we aimed to change the veterinary field, a role we will continue to play as a new R&D division within Boehringer Ingelheim,”
The financial terms of the deal have not been disclosed.
FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.
